Skip to Content

Join the 'Peritoneal Cancer' group to help and get support from people like you.

Peritoneal Cancer News

Related terms: Primary peritoneal cancer, Peritoneal carcinoma, Serous surface papillary carcinoma, Extra-ovarian serous carcinoma, Serous papillary carcinoma, Psammomacarcinoma

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Rituxan, Lung Cancer, Isotretinoin, Colorectal Cancer

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and for the liver and uterus in women. And improvements in cancer survival weren't equal for all Americans. "While this report found that five-year survival for most types of cancer improved among both blacks and whites over the past several decades, racial disparities for many common cancers have persisted, and they may have increased for prostate cancer and female breast cancer," said Dr. Lynne Penberthy. She's associate director of the U.S. National Cancer Institute's Surveillance Research ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Pancreatic Cancer, Skin Cancer, Ovarian Cancer, Endometrial Cancer, Osteosarcoma, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Bladder Cancer, Cervical Cancer, Melanoma - Metastatic

Zejula Approved for Certain Female Cancers

Posted 28 Mar 2017 by Drugs.com

TUESDAY, March 28, 2017 – Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk in response to platinum-based chemotherapy. Citing the National Cancer Institute, the FDA said in a news release that more than 22,000 women are expected to be diagnosed with these cancers this year, and more than 14,000 will die of these diseases. Zejula is designed to block an enzyme involved in repairing damaged DNA. The thought is that by blocking this enzyme, cancer cells would die and slow down or stop tumor growth, the FDA said. The drug was evaluated in clinical studies involving 553 people with any of these recurring cancers who had had their tumors shrunk by at least two doses of platinum-based chemotherapy. The average progression-free ... Read more

Related support groups: Cancer, Ovarian Cancer, Zejula, Solid Tumors, Peritoneal Cancer, Niraparib

Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer

Posted 27 Mar 2017 by Drugs.com

WALTHAM, MA, March 27, 2017 – Tesaro, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib), an oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response (CR or PR) to platinum-based chemotherapy. Zejula is the first PARP inhibitor to be approved by the FDA that does not require BRCA mutation or other biomarker testing. Tesaro anticipates launching Zejula in the United States in late April. Zejula is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a r ... Read more

Related support groups: Cancer, Ovarian Cancer, Zejula, Fallopian Tube Cancer, Peritoneal Cancer, Niraparib

Another Study Ties Obesity to Certain Cancers

Posted 1 Mar 2017 by Drugs.com

WEDNESDAY, March 1, 2017 – Carrying extra weight increases the risk of a number of cancers, a new review reports. Additional pounds appear to particularly influence the risk of cancers related to the digestive organs or those driven by hormonal abnormalities, according to the review's European authors. The evidence is so strong at this point that important organizations such as the International Agency for Research on Cancer describe "excess body weight as an important cause of cancers," said Susan Gapstur. She's vice president of epidemiology at the American Cancer Society. The new evidence review was led by Maria Kyrgiou, of Imperial College London's Department of Surgery and Cancer. The review found that a jump in a person's body mass index (BMI) of 5 was associated with a higher cancer risk in the esophagus, bone marrow, biliary tract system, pancreas and kidneys. BMI is a rough ... Read more

Related support groups: Obesity, Cancer, Weight Loss, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Endometrial Cancer, Stomach Cancer, Gastric Cancer, Wilms' Tumor, Solid Tumors, Peritoneal Cancer, Giant Cell Tumor of Bone, Neoplasm of Bone, Insulinoma

FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer

Posted 7 Dec 2016 by Drugs.com

South San Francisco, CA – December 6, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy. “With today’s approval of Avastin plus chemotherapy, women in the U.S. with recurrent, platinum-sensitive ovarian cancer now have a treatment option that showed a survival difference of more than five months compared to chemotherapy al ... Read more

Related support groups: Avastin, Ovarian Cancer, Bevacizumab, Peritoneal Cancer, Fallopian Tube Cancer

Global Recession May Have Contributed to Cancer Deaths

Posted 26 May 2016 by Drugs.com

THURSDAY, May 26, 2016 – The 2008 global economic crisis has been linked to a sharp rise in deaths from cancer, a new study reports. Unemployment and cuts in public health-care spending were associated with more than 260,000 additional cancer deaths by 2010. Most of those deaths – 160,000 – were in the European Union, the researchers said. The study included 70 countries and a total of more than 2 billion people, according to the report published online May 25 in The Lancet. "Cancer is a leading cause of death worldwide, so understanding how economic changes affect cancer survival is crucial," lead author Dr. Mahiben Maruthappu, of Imperial College London, said in a journal news release. "We found that increased unemployment was associated with increased cancer mortality, but that universal health coverage protected against these effects. This was especially the case for treatable ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Brain Tumor, Melanoma, Pancreatic Cancer, Skin Cancer, Ovarian Cancer, Endometrial Cancer, Bladder Cancer, Cervical Cancer, Melanoma - Metastatic, Stomach Cancer, Testicular Cancer, Gastric Cancer, Breast Cancer - Palliative, Peritoneal Cancer

Could Talk Therapy Ease Chemo-Related Memory Issues?

Posted 2 May 2016 by Drugs.com

MONDAY, May 2, 2016 – A type of psychotherapy might help cancer survivors deal with the long-term thinking problems some experience after chemotherapy, researchers say. It's estimated that about half of those who undergo chemotherapy for cancer develop what's often called "chemo brain." For instance, they may have trouble following conversations or remembering the steps in a project, according to background notes with the new study. Although usually mild, these changes can affect quality of life, job performance and relationships, said the researchers from the Eastern Maine Medical Center and Lafayette Family Cancer Center in Bangor, Maine. The researchers developed a cognitive-behavioral therapy (CBT) program called Memory and Attention Adaptation Training to help cancer survivors prevent or manage these memory problems. Their study involved 47 breast cancer survivors who underwent ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Prostate Cancer, Fluorouracil, Gleevec, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Pancreatic Cancer, Xeloda, Nausea/Vomiting - Chemotherapy Induced, Skin Cancer, Ovarian Cancer, Tasigna, Endometrial Cancer

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Tretinoin, Lupron Depot, Femara, Gleevec, Rituxan, Lung Cancer, Renal Cell Carcinoma, Isotretinoin

Ask a Question

Further Information

Related Condition Support Groups

Cancer

Related Drug Support Groups

Avastin, Zejula, bevacizumab, niraparib